Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
Status:
Recruiting
Trial end date:
2024-11-05
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study
to evaluate ICP-488.Efficacy, safety, PK, and PD characteristics in Chinese adults with
moderate to severe plaque psoriasis.